Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.40 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15225372 | 0.81 | HSP90AA1 (0.50) | ACHEMAPK1PNMTSLC6A5 | |
| SCHEMBL17877207 | 0.76 | BRD4 (0.56) | ACHEMAPK1SLC6A5 | |
| SCHEMBL2473215 | 0.75 | P2RX7 (0.42) | — | |
| SCHEMBL15225663 | 0.74 | HSP90AA1 (0.42) | — | |
| SCHEMBL15225529 | 0.72 | HSP90AA1 (0.41) | MAPK1 | |
| SCHEMBL15225276 | 0.72 | HSP90AA1 (0.41) | MAPK1 | |
| SCHEMBL13825814 | 0.72 | C5AR1 (0.42) | ACHEREV1PNMTC5AR1 | |
| SCHEMBL15225020 | 0.72 | HSP90AA1 (0.43) | MAPK1 | |
| SCHEMBL2469909 | 0.71 | HSP90AA1 (0.44) | — | |
| SCHEMBL15225169 | 0.71 | HSP90AA1 (0.43) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370437-B1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-04 | — | — | EP | disclosed |
| US-8309578-B2 | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-13 | — | — | US | disclosed |
| US-20110294790-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-01 | — | — | US | disclosed |
| EP-2370437-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010060854-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294790-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | HSP90AB1, HSP90AA1, HSP90AB2P | ACHE 3637/4885MAPK1 1630/4885REV1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.